Baricitinib Combination Therapy Demonstrates Significant Improvement in Cardiac Conduction Defects in Rapidly
Xiaoyan Su1, Huixia Wu1, Hairui Li2
1Department of Rheumatology and Immunology, the First Affiliated Hospital, Jinan University, Guangzhou, 510632, People's Republic of China.
Insights
Baricitinib (JAK inhibitor) shows promise in treating severe systemic sclerosis (SSc) with heart and lung complications. This combination therapy improved cardiac function, lung disease, and skin sclerosis in a refractory patient.
Area of Science:
- Rheumatology
- Immunology
- Cardiology
Background:
- Systemic sclerosis (SSc) is a complex autoimmune disease characterized by fibrosis affecting multiple organs.
- Refractory SSc with severe cardiac and pulmonary involvement presents significant management challenges and poor prognosis.
- Conventional treatments often yield limited efficacy in advanced SSc cases.
Objective:
To evaluate the efficacy of baricitinib in combination therapy for managing refractory, rapidly progressive systemic sclerosis (SSc) with severe cardiac conduction defects and interstitial lung disease (ILD).
Methods:
A 48-year-old male patient with SSc complicated by significant cardiac enlargement, third-degree atrioventricular block, heart failure, progressive ILD, and partial intestinal obstruction was included in the study. Prior treatments with mycophenolate mofetil (MMF), tacrolimus, and cyclophosphamide (CTX) had shown limited efficacy. The patient subsequently received a combination regimen of glucocorticoids, intravenous immunoglobulins, CTX, and baricitinib (4 mg daily).
Results:
The patient exhibited significant clinical improvements, including a reduction in cardiac size, restoration of sinus rhythm, and resolution of heart failure symptoms. ILD and skin sclerosis showed substantial regression. Pulmonary function tests indicated significant recovery in lung capacity and diffusion capacity. Additionally, gastrointestinal symptoms such as abdominal pain and bloating were completely resolved.
Conclusion:
This case highlights the potential of baricitinib as an adjunctive therapy for refractory SSc with multiorgan involvement. The observed improvements in cardiac conduction defects, ILD, and skin fibrosis suggest that JAK inhibitors may offer a promising therapeutic avenue for severe SSc cases resistant to conventional treatments.
More Related Videos
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
01:14Myocarditis III: Medical Management
01:17Pericarditis III: Medical Management
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:20Rheumatic Heart Disease IV: Nursing Management